Clinical Trial Update: 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing bevacizumab with taxane versus bevacizumab with exemestane as first-line treatment for metastatic breast cancer; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Exemestane (Exemestane)
• Taxane (paclitaxel or docetaxel)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: First Line Metastatic Breast Cancer | Phase 3 | Status: TERMINATED